Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00687505 · ClinicalTrials.gov registry record · Phase 1
Safety Study of FP-1039 To Treat Cancer
A Phase 1 study of Advanced Cancer, sponsored by Five Prime Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
- 2
- Study locations
NCT00687505 is a Phase 1 study of Advanced Cancer that has completed, run by Five Prime Therapeutics. The registered enrollment target is 39 participants, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (84% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00687505, a Phase 1 study of Advanced Cancer, has completed, sponsored by Five Prime Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary purpose of this study is to evaluate the safety and tolerability of FP-1039, a new biologic treatment for cancer.
Conditions Studied
Interventions
- DRUG FP-1039
Study Locations (2)
Michigan
- Karmanos Cancer Institute - Detroit
Texas
- START (South Texas Accelerated Research Therapeutics) - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2008-07 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00687505
The ClinicalTrials.gov registry entry for NCT00687505 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (84% lower). The listed sponsor is Five Prime Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Cancer appearing as the primary indexed condition, and to 1 intervention - of which FP-1039 is the first listed.
NCT00687505 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Michigan, Texas.
Frequently Asked Questions
What is clinical trial NCT00687505 about?
NCT00687505 is a clinical study titled "Safety Study of FP-1039 To Treat Cancer". The primary purpose of this study is to evaluate the safety and tolerability of FP-1039, a new biologic treatment for cancer.
What is the current status of trial NCT00687505?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2008-07. Estimated completion is 2011-06.
What conditions does trial NCT00687505 study?
This clinical trial studies the following conditions: Advanced Cancer.
What interventions are being tested in trial NCT00687505?
The interventions under investigation include: FP-1039 (DRUG).
Who is sponsoring clinical trial NCT00687505?
This trial is sponsored by Five Prime Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00687505 being conducted?
This trial has 2 study locations across Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in Patients With Advanced Cancers
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.